These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36342647)

  • 21. Evaluation of axillary reverse mapping (ARM) in clinically axillary node negative breast cancer patients - Randomised controlled trial.
    Abdelhamid MI; Bari AA; Farid MI; Nour H
    Int J Surg; 2020 Mar; 75():174-178. PubMed ID: 32059974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axillary reverse lymphatic mapping in breast cancer surgery: a comprehensive review.
    Seyednejad N; Kuusk U; Wiseman SM
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):771-81. PubMed ID: 24621187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal.
    Cebrecos I; Mension E; Alonso I; Castillo H; Sanfeliu E; Vidal-Sicart S; Ganau S; Vidal M; Schettini F
    Ann Surg Oncol; 2023 Aug; 30(8):4657-4668. PubMed ID: 36809608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axillary reverse mapping: a prospective study in women with clinically node negative and node positive breast cancer.
    Connor C; McGinness M; Mammen J; Ranallo L; Lafaver S; Klemp J; Fan F; Mahnken J
    Ann Surg Oncol; 2013 Oct; 20(10):3303-7. PubMed ID: 23975287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
    Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility study of axillary reverse mapping for patients with clinically node-negative breast cancer.
    Noguchi M; Noguchi M; Ohno Y; Morioka E; Nakano Y; Kosaka T; Kurose N; Minato H
    Eur J Surg Oncol; 2016 May; 42(5):650-6. PubMed ID: 27005806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy.
    Weber WP; Hanson SE; Wong DE; Heidinger M; Montagna G; Cafferty FH; Kirby AM; Coles CE
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438776. PubMed ID: 38815195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Che Bakri NA; Kwasnicki RM; Khan N; Ghandour O; Lee A; Grant Y; Dawidziuk A; Darzi A; Ashrafian H; Leff DR
    Ann Surg; 2023 Apr; 277(4):572-580. PubMed ID: 35946806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacy of Axillary Reverse Mapping for the Prevention of Lymphedema.
    Ruffino AE; Madera JD; Dearborn MM; Frank K; Oxenberg JC
    Am Surg; 2024 Feb; 90(2):199-206. PubMed ID: 37619219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper outer boundaries of the axillary dissection. Result of the SENTIBRAS protocol: Multicentric protocol using axillary reverse mapping in breast cancer patients requiring axillary dissection.
    Nos C; Clough KB; Bonnier P; Lasry S; Le Bouedec G; Flipo B; Classe JM; Missana MC; Doridot V; Giard S; Charitansky H; Charles-Nelson A; Bats AS; Ngo C
    Eur J Surg Oncol; 2016 Dec; 42(12):1827-1833. PubMed ID: 27769634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary treatment for operable primary breast cancer.
    Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: A retrospective multicenter study (KROG 21-06).
    Park Y; Shin YS; Kim K; Shin KH; Chang JH; Kim SS; Jung JH; Park W; Kim H; Kim YB; Ahn SJ; Kim M; Kim JH; Cha HJ; Kim TG; Park HJ; Lee SY
    Eur J Surg Oncol; 2023 Mar; 49(3):589-596. PubMed ID: 36470801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial.
    Tinterri C; Gentile D; Gatzemeier W; Sagona A; Barbieri E; Testori A; Errico V; Bottini A; Marrazzo E; Dani C; Dozin B; Boni L; Bruzzi P; Fernandes B; Franceschini D; Spoto R; Torrisi R; Scorsetti M; Santoro A; Canavese G;
    Ann Surg Oncol; 2022 Sep; 29(9):5732-5744. PubMed ID: 35552930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy.
    Tasdoven I; Balbaloglu H; Erdemir RU; Bahadir B; Guldeniz Karadeniz C
    Medicine (Baltimore); 2022 Dec; 101(52):e32545. PubMed ID: 36596061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The intraoperative assessment of sentinel nodes - Standards and controversies.
    van der Noordaa MEM; Vrancken Peeters MTFD; Rutgers EJT
    Breast; 2017 Aug; 34 Suppl 1():S64-S69. PubMed ID: 28673534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
    Appelgren M; Sackey H; Wengström Y; Johansson K; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Rydén L; Sund M; Alkner S; Vrou Offersen B; Filtenborg Tvedskov T; Christiansen P; de Boniface J;
    Breast; 2022 Jun; 63():16-23. PubMed ID: 35279508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.